![Pharmacokinetic and Safety Profile of the Novel HIV Nonnucleoside Reverse Transcriptase Inhibitor MK-8507 in Adults without HIV | Antimicrobial Agents and Chemotherapy Pharmacokinetic and Safety Profile of the Novel HIV Nonnucleoside Reverse Transcriptase Inhibitor MK-8507 in Adults without HIV | Antimicrobial Agents and Chemotherapy](https://journals.asm.org/cms/10.1128/AAC.00935-21/asset/259ab8aa-d52d-4bd2-8c04-8618895c984d/assets/images/large/aac.00935-21-f002.jpg)
Pharmacokinetic and Safety Profile of the Novel HIV Nonnucleoside Reverse Transcriptase Inhibitor MK-8507 in Adults without HIV | Antimicrobial Agents and Chemotherapy
![Safety, Tolerability and Pharmacokinetics Following Single- and Multiple-Dose Administration of the Novel NNRTI MK-8507 With a Midazolam Interaction Arm Safety, Tolerability and Pharmacokinetics Following Single- and Multiple-Dose Administration of the Novel NNRTI MK-8507 With a Midazolam Interaction Arm](https://www.natap.org/2020/images/101220/101220-3/1012201.gif)
Safety, Tolerability and Pharmacokinetics Following Single- and Multiple-Dose Administration of the Novel NNRTI MK-8507 With a Midazolam Interaction Arm
![Merck Suspends Clinical Development Of Non-nucleoside Reverse Transcriptase Inhibitor MK-8507 - Industry news - News - Hefei Home Sunshine Pharmaceutical Technology Co., Ltd Merck Suspends Clinical Development Of Non-nucleoside Reverse Transcriptase Inhibitor MK-8507 - Industry news - News - Hefei Home Sunshine Pharmaceutical Technology Co., Ltd](http://m.hsppharma.com/Content/uploads/2021524038/20211209173140cb4f54c5b2d94b90b8396aed2794281b.gif)